Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Conclusions: Ven + Nav in combination with chemotherapy is well tolerated, without any unexpected side effects and no DLTs observed to date. Preliminary data suggest that Ven + Nav with chemotherapy is efficacious in some patients with R/R ALL who have had multiple lines of therapy, including prior stem cell transplant. Enrollment, clinical follow-up, and correlative biology studies are ongoing.DisclosuresAlexander: Abbvie: Other: travel expenses. Jabbour: Bristol-Myers Squibb: Consultancy, Research Funding; Abbvie: Research Funding; Takeda: Consultancy, Research Funding; Novartis: Research Funding; Pfizer: Consultancy, Research Funding. Khaw: Abbvie: Research Funding; Amgen: Other: travel expenses, Research Funding; Bristol Myers Squibb: Research Funding; Jazz Pharmaceuticals: Research Funding; Novartis: Other: travel expenses. Mullighan: Cancer Prevention and Research Institute of Texas: Consultancy; Abbvie: Research Funding; Amgen: Honoraria, Speakers Bureau; Loxo Oncology: Research Funding; Pfizer: Honoraria, Research Funding, Speakers Bureau. Leonard: Amgen: Research Funding. Schmidt: Abbvie: Employment, Equity Ownership. Tong: Abbvie: Employment, Equity Ownership. Zhou: Abbvie: Employment, Equity Ownership. Ross: AbbVie, Inc: Employment, Equity Ownership. Rosenwinkel: Abbvie: Employment, Equity Ownership. Jacobson: Abbvie: Employment, Equity Ownership. Kim: Abbvie: Employment, Equity Ownership. Stock: Jazz Pharmaceuticals: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Alexander, T., Lacayo, N. J., Pullarkat, V. A., Jabbour, E. J., Khaw, S. L., Mullighan, C. G., Bajel, A., Leonard, J., Norris, R., Rubnitz, J., Vear, S. I., Schmidt, M., Tong, B., Zhou, Y., Ross, J. A., Rosenwinkel, L., Jacobson, A., Kim, S. Y., Stock, W. Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III Source Type: research